TPWA
VIR icon

Twin Peaks Wealth Advisors’s Vir Biotechnology VIR Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-85
Closed -$762 – 2127
2026
Q1 		$762 Buy
+85
New +$677 ﹤0.01% 1959

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Twin Peaks Wealth Advisors's VIR Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Vir Biotechnology (VIR) in Q2 2026, closing a stake of 85 shares — an estimated $762 sold.

Twin Peaks Wealth Advisors first reported a position in VIR in Q1 2026 and held it in 1 quarter. The position peaked at $762 in Q1 2026. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining Vir Biotechnology position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 85 Vir Biotechnology shares in Q2 2026, an estimated $762.
  • Twin Peaks Wealth Advisors first reported a position in Vir Biotechnology in Q1 2026 and held it in 1 quarter.
  • Twin Peaks Wealth Advisors's Vir Biotechnology position peaked at $762 in Q1 2026.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.